Grace Therapeutics reports Q3 EPS (36c), consensus (46c)

“During our third quarter and in subsequent weeks we continued to make significant progress in both clinical and corporate goals, announcing positive topline data from our Phase 3 STRIVE-ON safety trial, and securing up to $30 million in gross proceeds from a private placement financing with leading healthcare investors,” said Prashant Kohli, CEO of Grace Therapeutics (GRCE). “Data from our STRIVE-ON trial exceeded our expectations, demonstrating that GTx-104 was associated with improved clinical outcomes for patients when compared to patients treated with orally administered nimodipine. Importantly, the data also provides both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in aSAH patients, which could help drive adoption of GTx-104 by neurocritical care physicians and hospital pharmacies.”